27.3 C
Vientiane
Sunday, September 14, 2025
spot_img
Home Blog Page 1356

JULIEN’S AUCTIONS PRESENTS BOLD LUXURY: THE LIMELIGHT EDIT

Featuring Iconic Fashion from Marilyn Monroe, Elizabeth Taylor, Cher, Victoria Beckham, Amy Winehouse, Hermes, Chanel, Giambatista Valli & More

A Landmark Sale of Fashion and Hollywood Iconography

Live at The Peninsula Beverly Hills | March 27, 2025
Online Registration & Bidding Opens: February 27, 2025

BEVERLY HILLS, Calif., Feb. 27, 2025 /PRNewswire/ — Julien’s Auctions, the industry leader in high-profile luxury and celebrity memorabilia sales, proudly announces Bold Luxury: The Limelight Edit, an exclusive auction featuring some of the most sought-after designer fashion and celebrity-worn pieces. Taking place on March 27, 2025, at The Peninsula Beverly Hills, this premier event will bring together collectors, investors, and fashion aficionados to bid on a meticulously curated selection of rare and historic pieces.

A Defining Moment for Luxury and Celebrity Collectibles

From Marilyn Monroe to Elizabeth Taylor, Cher, and Britney Spears, this extraordinary collection represents the pinnacle of Hollywood glamour and haute couture. Each piece embodies a cultural legacy, offering a rare opportunity to own tangible history.

“Bold Luxury is a celebration of fashion’s most iconic moments. These one-of-a-kind artifacts transcend mere clothing—they represent the intersection of style, storytelling, and investment,” said Martin Nolan, Co-Founder and Executive Director of Julien’s Auctions.

Auction Highlights

Elizabeth Taylor:
  • 14K Gold and Diamond Evening Purse
  • Art Deco Emerald and Diamond Brooch, Circa 1935
Marilyn Monroe:
  • 1961 The Misfits Cowboy Boots from the Personal Collection of Dee & Tommy Hilfiger.
  • 1954 Jeans from “River of No Return” from the Personal Collection of Dee & Tommy Hilfiger.
Cher & Britney Spears:
  • Cher’s 2002 Stage-Worn If I Could Turn Back Time Costume by Bob Mackie
  • Britney Spears’ 2001 Bob Mackie Jubilee Burlesque Ensemble
Luxury Fashion Pieces:
  • Hermès Limited Edition Framboise Matte Alligator Birkin
  • Paco Rabanne 1999 Spring Haute Couture Dress

Luxury as an Investment

As the luxury collectibles market grows, designer fashion and celebrity memorabilia gain value. Julien’s Bold Luxury series captures this shift, attracting both seasoned and new collectors.

How to Bid

  • Online Registration & Bidding Open: February 27, 2025
  • Live Auction: March 27, 2025, The Peninsula Beverly Hills
  • Bid Online: www.juliensauctions.com

This must-attend event redefines bold luxury, offering a front-row seat to history.

For more information about Julien’s Auctions or any additional questions, please contact:

Media Contact
Jenelle Hamilton PR
Jenelle Hamilton
jenelle@jenellehamlton.com
+1 646.421.9139

Video – https://www.youtube.com/watch?v=zhzV06CED_8

 

Open Compute Project Foundation and JEDEC Drive Open Silicon Innovation

New Chiplet Design Kits Enable New Silicon Supply Chains

AUSTIN, Texas, Feb. 27, 2025 /PRNewswire/ — Today, the Open Compute Project Foundation (OCP), the nonprofit organization bringing hyperscale innovations to all, and JEDEC Solid State Technology Association, the global leader in the development of standards for the microelectronics industry, announce the availability of new Chiplet Design Kits for use with today’s EDA tools covering Assembly, Substrate, Material and Test developed in collaboration within the OCP Open Chiplet Economy Project. Leveraging the alliance between OCP and JEDEC, these design kits are now part of the Global World Wide Standard JEDEC JEP30: Part Model Guidelines.


The release of the Assembly, Substrate, Material, and Test Design Kits build on earlier joint efforts between the OCP and JEDEC integrating OCP Chiplet Data Extensible Markup Language (CDXML) specification into  JEDEC JEP30: Part Model Guidelines, enabling Chiplet builders to provide electronically a standardized Chiplet part description to their customers, paving the way for automating System-in-Package (SiP) design and build using Chiplets.

“The new design kits, developed through collaboration between OCP and JEDEC, promote innovation in SiP design by fostering collaboration and openness, ensuring broad accessibility, and supporting rapid adoption across the semiconductor industry. These kits promote openness, streamline design workflows, and reduce manual interventions, thereby significantly improving design efficiency, scalability, and innovation,” said James Wong, Palo Alto Electron, David Ratchkov, Thrace Systems and Michael Durkan, Chair of the JEDEC JEP30 Task Group. The integration of the design kits with the rest of the PartModel enforces consistent terminology across the Chiplets and the rules that support the development of SiP, eliminating the need for re-mapping within the design tools.

  • The Assembly and Substrate Design Kits enables efficient integration of heterogeneous Chiplets by defining standardized rule formats and tolerances for key design elements such as geometries, layers, interconnects and assembly processes.
  • The Material Design Kit provides a comprehensive framework for defining, evaluating, and validating the material properties and design parameters required for SiP. It focuses on critical elements such as substrates, interposers, redistribution layers and 3D integration technologies. The kit emphasizes the importance of material properties, such as dielectric constants, thermal conductivity and mechanical strength, to optimize performance, reliability and cost-efficiency.
  • The Test Design Kit, which is being standardized within JEDEC, enables the planning, design and manufacturing of SiP, with a particular emphasis on testability, enabling standardization of the testing process for Chiplet integration, with a focus on standard definitions for test elements, test flow requirements and definition of test-only elements, and support for test in advanced manufacturing.

“Chiplets have rapidly become the efficient and cost-effective way to develop chips at leading-edge nodes, and have been used successfully to improve SiP performance with cost efficiencies at scale, because the entire chip development cycle is managed in-house at large companies. To provide an open environment where designers drop known-good third-party sourced Chiplets into their designs requires the development of an open marketplace. Recently the OCP took the next step in establishing an Open Chiplet Economy with the opening of the OCP Chiplet Marketplace.  Moving forward the OCP intends to become the front door to an open Chiplet marketplace, making available a catalogue of standalone Chiplets, new standardizations, tools and best practices that would be required for a truly open economy,” said Cliff Grossner, Ph.D., Chief Innovation Officer at the Open Compute Project Foundation.

The schemas included in the Assembly, Materials and Test design kits as integrated into the JEDEC JEP:30 Part Model Guidelines have been designed to scale to a very large number of Chiplet interconnection points while keeping the schema size manageable. Security is also of utmost importance and all schema files are digitally signed to ensure no corruption, when shared between chiplet buyer to seller.

“There are still many opportunities to create additional standardization efforts bringing together JEDEC’s strength in setting global standards for the microelectronics industry with OCP’s expertise in specifying system level devices seeding emerging technologies and markets. JEDEC is delighted with this next step in the collaboration with OCP moving the market forward,” said John Kelly, President, JEDEC. 

“The next inflection point for the silicon supply chain is open, with innovation driven by a collaborative community, just as we have seen with the computing platforms of the cloud computing era. Developing an open stand-alone Chiplet silicon supply chain will require a rethink of this supply chain. Many design decisions made by Chiplet designers will impact packaging, test and verification, and the software stack, which will all be done by separate organizations, unlike today, where most silicon design is done in-house using proprietary processes,” said Tom Hackenberg, Principal Analyst in Computing & Software at Yole Group.

About the Open Compute Project Foundation
The Open Compute Project (OCP) is a global collaborative Community of hyperscale data center operators, telecom, colocation providers and enterprise IT users, working with the product and solution vendor ecosystem to develop open innovations deployable from the cloud to the edge. The OCP Foundation is responsible for fostering and serving the OCP Community to meet the market and shape the future, taking hyperscale-led innovations to everyone. Meeting the market is accomplished through addressing challenging market obstacles with open specifications, designs and emerging market programs that showcase OCP-recognized IT equipment and data center facility best practices. Shaping the future includes investing in strategic initiatives and programs that prepare the IT ecosystem for major technology changes, such as AI & ML, optics, advanced cooling techniques, composable memory and silicon. OCP Community-developed open innovations strive to benefit all, optimized through the lens of impact, efficiency, scale and sustainability. Learn more at www.opencompute.org.

About JEDEC
JEDEC is the global leader in the development of standards for the microelectronics industry. Thousands of volunteers representing over 350 member companies work together in more than 100 JEDEC committees and task groups to meet the needs of every segment of the industry, manufacturers and consumers alike. The publications and standards generated by JEDEC committees are accepted throughout the world.  All JEDEC standards are available for download from the JEDEC website. For more information, visit www.jedec.org.

Media Contacts
Dirk Van Slyke
Open Compute Project Foundation
dirkv@opencompute.org  
Mobile: +1 303-999-7398
(Central Time Zone/CST/Austin, TX)

Emily Desjardins
JEDEC
703-907-7560
emilyd@jedec.org
(Eastern Time Zone/EST/Arlington, VA)

 

Mainstream Renewable Power Appoints Morten Henriksen as CEO

FORNEBU, Norway, Feb. 27, 2025 /PRNewswire/ — The Board of Mainstream Renewable Power (“Mainstream”), the pureplay global wind and solar company majority-owned by Aker Horizons ASA, is pleased to announce the appointment of Morten Henriksen as Group CEO, effective April 1, 2025. Henriksen comes from the position of CEO of Gassnova, the Norwegian state enterprise for carbon capture and storage. His previous experience spans executive management roles in the energy industry in Norway and internationally for companies including Arendals Fossekompani and Statkraft, in addition to multiple board positions.

Current CEO Mary Quaney will continue to support Mainstream and the transition in a Senior Advisor capacity before stepping down in the second half of 2025 to pursue other interests.

The appointment comes as the Company implements its updated strategy, continuing to deliver significant cost base reduction targets and sharpening its focus on three core growth markets where it sees the greatest potential for value creation – South Africa, Australia, and the Philippines.

In order to reduce costs and leverage the resources of its majority shareholder Aker Horizons, Mainstream is relocating its headquarters from Dublin to Oslo in the first half of 2025. This is in line with its plan to reduce its cost base by approximately 65% by 2026, relative to 2023 levels.

Mainstream’s Chairman, Kristian Røkke, said: “We would like to express our gratitude to Mary for her leadership over the last five years. She has guided Mainstream’s global team with focus, resilience and integrity, navigating a period of industry-wide transformation.”

He continued: “As we enter a new phase, Morten brings extensive experience and deep sector expertise to position Mainstream for growth. His leadership will be instrumental in executing the Company’s strategy and driving Mainstream’s growth in the global energy market.”

Commenting on his appointment, Morten Henriksen said: “Mainstream is well positioned for the opportunities ahead. I am very excited about implementing our vision to build a lean and focused renewable energy company, leading in our core markets and creating value through strong project execution, a lean cost base and capital efficiency.”

For further information, please contact:
Jonas Gamre, Investor Relations, tel: +47 97 11 82 92,
email: jonas.gamre@akerhorizons.com
Mats Ektvedt, Media, tel: +47 41 42 33 28,
email: mats.ektvedt@corporatecommunications.no

About Aker Horizons

Aker Horizons develops green energy and green industry to accelerate the transition to Net Zero. The company is active in renewable energy, carbon capture and sustainable industrial assets. As part of the Aker group, Aker Horizons applies industrial, technological and capital markets expertise with a planet-positive purpose to drive decarbonization globally. Aker Horizons is listed on the Oslo Stock Exchange and headquartered in Fornebu, Norway. Across its portfolio, the company is present on five continents. www.akerhorizons.com

About Mainstream Renewable Power

Mainstream Renewable Power is a leading pure-play renewable energy company with wind and solar assets across Europe, Latin America, Africa, and Asia-Pacific. Mainstream is one of the most successful developers of gigawatt-scale renewables platforms, across onshore wind, offshore wind, and solar power generation. The company has successfully delivered 6.6 GW of wind and solar generation assets to financial close-ready and has a global project portfolio of 22.7 GW. www.mainstreamrp.com

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/aker-horizons/r/mainstream-renewable-power-appoints-morten-henriksen-as-ceo,c4111882

 

Ubie and Nucleus Genomics Partner to Enhance Access to Genetic Testing and Drive Early Screening for Improved Health Outcomes

  • Genetic testing can be critical to ensuring the early diagnosis and proper treatment of serious disease for patients of all ages
  • The partnership combines Ubie’s AI-driven symptom identification and high rates of patient engagement with Nucleus Genomics’ cutting-edge complete DNA sequencing
  • Engaging with patients while they are looking for answers for their health issues makes it possible to identify potential genetic disorders early in the healthcare journey

NEW YORK, Feb. 27, 2025 /PRNewswire/ — Ubie, a global healthcare AI platform that guides patients to better interactions with providers and life sciences, and Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the outcomes of a partnership to improve access to genetic screening and early disease detection. The collaboration leverages Ubie’s AI-powered Symptom Checker and Nucleus Genomics sophisticated genetic testing capabilities to address care gaps and underdiagnosis in healthcare by connecting individuals who may have undiagnosed conditions with advanced genetic screening options early in the care journey.

A genetic disorder is a disease caused by a change in the DNA sequence. These mutations can be inherited or occur spontaneously leading to a wide range of health issues depending on which gene is affected. Genetic testing can help guide decisions about medical care by effectively diagnosing the disease and ensuring proper treatment. With Ubie’s ability to reach patients before their diagnosis, genetic testing can give patients a head start on identifying mutations and guidance on the right course of action, which can include lifestyle changes, preventative measures and earlier treatment with personalized medicine.

A growing leader in the diagnostics space, Nucleus Genomics expands access to genetic screening and testing beyond what patients may be able to get from their regular healthcare providers. The company is using its partnership with Ubie to reach more and better motivated patients, and expand and diversify its user base.

“Nucleus Genomics is committed to driving innovation in genetic testing in order to get patients the answers they need at the right point in their care journey,” said Halle Marchese, Director of Marketing & Communications at Nucleus Genomics. “Initial results from our partnership with Ubie have shown outstanding engagement, connecting us with motivated consumers actively seeking answers about their health to get the insights and genetic counseling they need to make informed and impactful decisions about their care.”

The partnership focuses on several key areas, including the early detection of genetic predispositions to various health conditions, improved access to genetic screening for underserved populations, enhanced patient education about genetic factors in common and rare diseases, and personalized health insights based on both symptoms and genetic markers.

Leveraging Ubie, Nucleus reached more than 277,000 patients in the first four months. Outcomes highlighted the value of ultra-targeted messaging, as target users clicked-through nearly 10x higher than healthcare benchmarks. By matching patients with disease-specific genetic education, Ubie also increased engagement more than 30% relative to baseline.

Furthermore, Ubie diversified Nucleus’s representation, reaching  patients ranging from 18 to 90 years of age, with 87% over 50, and 82% of users identifying as female – a focus for Nucleus Genomics. Engagement for rare diseases and progressive conditions saw even higher engagement, outperforming Ubie’s average by approximately 200%, further supporting the recent launch of Nucleus Genomics rare disease panel screening.

“This partnership represents a significant step forward in democratizing access to genetic testing. This will empower patients, who are already actively searching for answers, to take control of their care,” said Kota Kubo, Co-Founder and CEO of Ubie. “This partnership is an example of how connecting disparate pieces of healthcare and providing patients with the insights they need can have an impact on appropriate care and outcomes.”

Previously, most consumer genetic tests used microarray testing, which looks at less than 0.1% of DNA sequencing, meaning that important health insights can be missed. Nucleus Genomics analyzes 100% of a patient’s DNA, with 30x high-depth whole-genome sequencing coverage, providing a more complete picture and insights on genetic risk for 900+ conditions.

Nucleus Genomics is a medical provider delivering whole-genome sequencing, cancer screening, heart screening and neurology screening. The company’s recent $14 million Series A funding round highlights its effectiveness and impact in the market, with the company looking to dramatically expand its genetic risk assessments and add features to help users plan healthy families.

About Nucleus Genomics

Nucleus is redefining next-generation genetic testing and analysis. By combining polygenic scores with traditional rare variant DNA analysis, the company provides comprehensive assessments of genetic disposition across a myriad of diseases and traits. Nucleus’ mission is to empower people to take agency over their health so no one dies from preventable disease — that’s why the company is building a platform based on cutting-edge science, where everyone has their genome at their fingertips, complete clarity on their risks, and are empowered by personalized health measures. Learn more at mynucleus.com.

About Ubie

Founded in 2017, Ubie empowers individuals and healthcare professionals with the tools they need for better care. Leveraging cutting-edge disease prediction AI, Ubie guides 10+ million patients every month to seek appropriate medical attention through its free online Symptom Checker and equips 1,500+ provider organizations with clinical tools that streamline workflows and support better diagnoses and health outcomes. Trained on medical data, Ubie’s marketing solutions power advanced targeting capabilities and high-performing digital campaigns for 70% of the world’s top life science companies.

Learn more about our vision and work at https://ubiehealth.com/company or try our free Symptom Checker at https://ubiehealth.com/.

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

PROVIDENCE, R.I., Feb. 27, 2025 /PRNewswire/ — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and spearheaded the development of a new computational platform for developing personalized, neoantigen-based cancer vaccines: Ancer®. He subsequently oversaw translational work of this technology at EpiVax’s subsidiary company, EpiVax Therapeutics, Inc., from 2019 to 2024. Dr. Richard is now leading innovation efforts at EpiVax and is overseeing the development of new and enhanced computational tools for immunogenicity assessment. He holds a M.Eng. in Bioinformatics and Modeling from the National Institute of Applied Sciences (INSA) of Lyon, France, and a Ph.D. in Bioinformatics from Boston University.

The promotion of Dr. Richard coincides with several key advancements in EpiVax’s technology and offerings. EpiVax reports significant updates, leveraging advanced artificial intelligence (AI) and machine learning (ML) techniques, to several of the core immunoinformatic assets included in the company’s ISPRI platform. The updates will further enhance the leading platform’s immunogenicity risk assessment features for biologic therapeutics. The new models have enabled EpiVax researchers to refine prediction of tolerated epitopes, improving both precision and recall of its JanusMatrix model by 50%. In addition, new immunogenicity models predicting the rate of anti-drug antibodies (ADA) against monoclonal therapeutics have led to a 6-fold increase in the correlation between predicted and observed values over existing approaches, while significantly reducing the rate of false negative (low predicted immunogenicity / high observed immunogenicity) by 85%. These updated tools will become available on EpiVax’s ISPRI platform, accessible on a SaaS and fee-for-service basis in coming months, enhancing accuracy of results of a key assessment step in the development process for global biotech and pharma clients and collaborators.

In addition, EpiVax has filed a new Model Master File (MMF) for its PANDA® In Silico Model to the FDA, supporting regulatory filing of Abbreviated New Drug Applications (ANDA) of generic peptide drugs. EpiVax’s PANDA® MMF provides detailed descriptions of its models and methodologies for assessing the immunogenicity of peptide drugs and their impurities and can now be referenced as a Drug Master File (DMF) in FDA ANDA fillings. The accessibility of EpiVax’s PANDA® MMF represents an important step in streamlining the preparation and review of ANDAs, enabling sponsors to simplify their regulatory package and FDA reviewers to access in-depth background and validation information regarding  EpiVax’s immunogenicity models.

EpiVax remains committed to driving innovation with several planned improvements for the ISPRI platform upcoming, including a new version of EpiMatrix® to further enhance the toolkit’s predictive capabilities. Additionally, guided analysis features and an updated user interface for ISPRI will provide a more user-friendly experience, empowering our partners in strengthening their pipelines.

About EpiVax
EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapeutics, and vaccines. EpiVax partners with a global roster of companies, agencies, and academics to accelerate immunogenicity risk assessment, immune modulation, and rapid vaccine design.

Press Contact
Sarah Moniz
Director, Business Development
EpiVax
smoniz@epivax.com

Databricks Achieves FedRAMP High Authorization for AWS GovCloud

Hires industry veteran Mike Daniels to lead public sector practice amid rapidly growing demand for data intelligence 

SAN FRANCISCO, Feb. 27, 2025 /PRNewswire/ — Amid the growing momentum of its Public Sector business, Databricks, the Data and AI company, announced today that it has received Federal Risk and Authorization Management Program (FedRAMP®) High authorization from the FedRAMP Program Management Office (PMO) for its Data Intelligence Platform on Amazon Web Services (AWS) GovCloud. This authorization builds on the company’s support for Department of Defense (DoD) Impact Level 5 (IL5) Provisional Authorization (PA) and Azure Databricks’ FedRAMP High and IL5 authorizations, demonstrating a continued commitment to meeting the federal government’s requirements for handling highly sensitive Controlled Unclassified Information (CUI). In addition to Databricks’ investments to make its commercial products FedRAMP authorized, the data intelligence leader strengthened its leadership team, hiring Mike Daniels as Vice President and General Manager of Public Sector.

Public sector organizations have the opportunity to positively impact the lives of their citizens with data. Yet, these organizations face significant challenges because of the lack of modern commercial cloud technology available to them. This often results in bespoke software development or the use of old technology that isn’t capable of unlocking the value of their data or leveraging AI. The Databricks Data Intelligence Platform helps more than 400 public sector and related organizations, including 80% of the executive departments of the U.S. federal government, harness the power of their data for analytics, machine learning and AI applications. Built on an open source foundation, the platform enables organizations to drive innovation to increase revenue, lower costs, and reduce risk. Public sector customers use the Data Intelligence Platform to improve national security, streamline the path to citizenship, protect against fraud and waste and optimize government operations.

FedRAMP High Authorization on AWS GovCloud
By achieving FedRAMP High authorization on AWS GovCloud, Databricks enables government agencies and organizations that work with the U.S. government to accelerate innovation while minimizing risk when working with highly sensitive private and public sector data. Now, these agencies have access to commercially available technology, including the ability to leverage the latest innovations in agentic AI, while complying with the privacy, security, and related controls required by the U.S. government.

“Working with public sector organizations for more than a decade, we know how critical it is for global governments to modernize in order to complete their mission. Data is a critical part of decision-making in the government and Databricks is enabling government agencies to understand their organization’s data, identify waste, pass audits, and gain efficiencies — all while remaining secure and compliant,” said Rory Patterson, Chairman of the Board of Databricks Federal. “We’ve completed countless transformative public sector projects, modernizing these agencies with our Data Intelligence Platform, but we know we can still do more to help agencies transform into the organizations of the future. With a significant increase in demand over the last two years for our commercial platform in the Public Sector, I am incredibly excited Mike is joining us to lead its continued growth and help us unblock more public sector programs and showcase what is possible when the government has access to modern commercial software.”

Mike Daniels Joins as VP and GM of Public Sector
With more than 30 years of industry leadership, Mike Daniels will lead Databricks’ growing Public Sector practice. He will be responsible for ensuring public sector customers successfully adopt the Databricks Data Intelligence Platform to achieve their organizations’ missions. He will also help scale Databricks’ Public Sector go-to-market operations. Prior to Databricks, Daniels held several public sector sales leadership positions, including roles at Google, Salesforce, Oracle, and UiPath.

“Every public sector organization wants to leverage data and AI to fuel efficiency and innovation and drive their missions forward. We want to make that as easy, collaborative and cost-effective as possible for them while upholding the security standards and protocols these agencies require,” said Daniels. “Today, building domain-specific AI applications on your trusted data — what we call data intelligence — is an imperative. I am thrilled to join Databricks to help more public sector agencies drive value for their organizations with the most innovative data and AI platform on the market.”

Community and Department of Defense Offerings on AWS GovCloud
To help more public sector organizations access the Databricks Data Intelligence Platform in compliance with FedRAMP High, DoD IL5, and International Traffic in Arms Regulations (ITAR), the Databricks AWS GovCloud DoD and Databricks AWS GovCloud Community offerings are now generally available. The Databricks AWS GovCloud DoD offering is available exclusively for the DoD, while the Government Community offering is available for non-DoD government agencies and contractors.

Join Databricks and its government customers and partners on Thursday, March 27, at the third annual Databricks Public Sector Forum, a full-day program for leaders to learn more about Databricks’ solutions for the Public Sector and how data intelligence can enable the mission of government. To learn more about Databricks’ federal government customers, visit the Data Intelligence Platform for Public Sector page. Find more information on security and FedRAMP compliance of Databricks services in the Databricks Security and Trust Center.

About Databricks
Databricks is the Data and AI company. More than 10,000 organizations worldwide — including Block, Comcast, Condé Nast, Rivian, Shell and over 60% of the Fortune 500 — rely on the Databricks Data Intelligence Platform to take control of their data and put it to work with AI. Databricks is headquartered in San Francisco, with offices around the globe and was founded by the original creators of Lakehouse, Apache Spark™, Delta Lake and MLflow. To learn more, follow Databricks on X, LinkedIn and Facebook.

Contact: Press@databricks.com

COMPLEX PRESENTS TAKASHI MURAKAMI x MLB LIMITED EDITION COLLECTION FOR 2025 MLB TOKYO SERIES

Set to Release March 7, the Collection Marks Murakami’s Most Extensive Partnership with MLB and Highlights the Los Angeles Dodgers and Chicago Cubs

LOS ANGELES, Feb. 27, 2025 /PRNewswire/ — Today, Complex is unveiling the Takashi Murakami x MLB Tokyo Series collection, set to launch on March 7, 2025. The exclusive partnership highlights the collaboration between the renowned Japanese contemporary artist Takashi Murakami and Major League Baseball (MLB), bringing together two cultural icons to celebrate two of the league’s most storied teams for a limited-edition collection of collectibles and merchandise.

COMPLEX PRESENTS TAKASHI MURAKAMI x MLB LIMITED EDITION COLLECTION FOR 2025 MLB TOKYO SERIES
COMPLEX PRESENTS TAKASHI MURAKAMI x MLB LIMITED EDITION COLLECTION FOR 2025 MLB TOKYO SERIES

In celebration of the 2025 MLB Tokyo Series Presented by Guggenheim taking place March 18-19 at the Tokyo Dome between the Chicago Cubs and the defending World Series champion Los Angeles Dodgers, the collection celebrates the deep cultural connection between America’s favorite pastime and its influence in Japan. Featuring Murakami’s iconic vibrant colors and playful motifs, the exclusive series brings a fresh, artistic perspective to MLB merchandise and memorabilia, making it a must-have for baseball fans, art enthusiasts and collectors.

“I think this new collection builds upon the historical friendship between Japan and the United States,” said Takashi Murakami. “I feel lucky to be able to work alongside Complex, MLB and highlight Shohei Ohtani, an outstanding athlete who has emerged from Japan and made a name for himself on the global stage. This is something I am overwhelmed with gratitude to be a part of.”

Takashi Murakami x MLB Tokyo Series Collection

The Complex collaboration brings together two of MLB’s most iconic teams: the Los Angeles Dodgers and Chicago Cubs, infusing Murakami’s signature style across an array of exclusive products from global sports platform Fanatics, including Nike MLB t-shirts and hoodies, alongside signature pieces – official Nike Los Angeles Dodgers and Chicago Cubs MLB Limited jerseys. The Fanatics apparel collection, which will incorporate Murakami’s iconic floral artwork, will also be available on individual player Nike MLB Limited jerseys for Dodgers players Shohei Ohtani, Yoshinobu Yamamoto, Mookie Betts and Freddie Freeman and Cubs players Shota Imanaga, Seiya Suzuki, and Dansby Swanson.

In addition to wearable merchandise, the collection will also include Topps trading cards, New Era 59FIFTYs, knits and adjustable caps, Rawlings® baseballs and gloves, Victus bats, totes, keychains and more.

As part of the collaboration, Murakami’s Ohana Hatake, a first-of-its-kind brand led by the legendary artist, will introduce two brand new, limited-edition slides. The new release embodies Murakami’s iconic flower motif and showcases the Chicago Cubs and Los Angeles Dodgers logos on the inventive Surippa Ohana silhouette.

The Takashi Murakami x MLB Limited Edition 2025 Tokyo Series Collection will be available to buy on Complex.com (including Complex exclusives), Fanatics.com and MLBShop.com beginning March 7. Select products will also be available at the MLB Tokyo Series games, Dodger Stadium, Wrigley Field and Clubhouse stores as well as the MLB Flagship Store in New York City.

Topps x MLB Tokyo Series Matchup Set

A special 2025 Topps x Murakami MLB Tokyo Series Matchup Set will be available exclusively through Complex Shop (SRP $120). The collection includes a 25-card complete set, featuring Murakami artwork that celebrates top players from both the Chicago Cubs and Los Angeles Dodgers, including Shohei Ohtani, Yoshinobu Yamamoto, Seiya Suzuki and Shota Imanaga. The set also has rare parallels and autographs, with the chase card being a one-of-one dual-autograph card of Murakami and Ohtani, sure to be one of the most desirable and rare cards of all time. Each limited-edition box will contain: one 25-card complete set, one serial-numbered base card parallel /199 or lower.

“Complex is proud to bring together Takashi Murakami and two of the biggest teams in MLB to celebrate this historic sports moment in Tokyo. This once-in-a-lifetime collaboration merges Murakami’s unmistakable artistry with the global energy of baseball, capturing the essence of the city and the deep cultural connection between art and sport,” said Aaron Levant, Complex CEO.

Exclusive Complex Pop-Ups

Fans can immerse themselves in the Takashi Murakami x MLB collaboration at exclusive Complex pop-up events in Tokyo and Los Angeles. Each event will showcase the limited-edition merchandise, Murakami-inspired installations, and historical MLB vignettes, offering fans a chance to engage with both the collection and Murakami’s visionary artwork. The events lead off in Los Angeles from March 7-9 at Complex LA (433 N Fairfax Ave, Los Angeles, CA 90048), followed by Japan, March 8-21 from 11:00am – 6:00pm JST, at 1 Chome-20-6 Jingumae, Shibuya, Tokyo 150-0001, Japan. Consumers can reserve a time slot at the Tokyo pop-up HERE and all purchases will be limited to three items total.

For more information on the Takashi Murakami x MLB Tokyo Series collection, please visit: Complex.com and follow ComplexMLB and Fanatics.

ABOUT COMPLEX

Complex is the definitive platform for global youth culture and music lifestyle, seamlessly integrating cutting-edge content, commerce and live experiences with unparalleled scale.

Whether through video, long-form text, or social media, Complex tells stories of streetwear and style, music, sports, art and beyond. Its content engages in a dynamic conversation with the audience, reflecting and shaping the zeitgeist of convergence culture.

A powerful media juggernaut paired with a curated marketplace, Complex is redefining the way fans interact with their favorite brands and artists and reshaping the future of digital culture and commerce. Complex’s strategic partnership with Universal Music Group will deliver unparalleled experiences and exclusive collaborations to passionate music fans.

ABOUT TAKASHI MURAKAMI

The originator and proponent of Superflat theory, which reconstructs Japanese traditional paintings and the origin of Japanese contemporary art through visual premises of anime and manga. Murakami has created numerous characters including Miss Ko2 and Mr. DOB that reflect the otaku culture and presents them in the forms of intentionally kitsch sculptures and acutely two-dimensional paintings antithetical to the Western perspective techniques. Murakami’s cultural theory based on subcultures not only deconstructs the highbrow/lowbrow hierarchy but critically illustrates the post-World War II Japanese psychology, establishing a discourse unique to Japan in the increasingly globalizing art scene. The artist continues to attract a wide-ranging audience beyond contemporary art through his multifaceted activities including his collaboration with Louis Vuitton and focuses on street culture and contemporary ceramics. The final installment of his Superflat trilogy of curated exhibitions, Little Boy: The Arts of Japan’s Exploding Subculture (New York, 2005), was awarded The Best Thematic Museum Show in New York by AICA that year. His first retrospective, ©MURAKAMI (2007 – 2009) toured four cities in North America and Europe, starting with the Museum of Contemporary Art, Los Angeles. He has since been holding major solo exhibitions around the world, including at the Palace of Versailles (2010), Al RiwaqExhibition Hall (Doha, 2012), the Mori Art Museum (Tokyo, 2015), the Garage Museum of Contemporary Art (Moscow, 2017), Tai Kwun Contemporary (Hong Kong, 2019), The Broad (Los Angeles, 2022), Asian Art Museum of San Francisco (San Francisco, 2023), and Kyoto City KYOCERA Museum of Art (Kyoto, 2024).

ABOUT MAJOR LEAGUE BASEBALL

Major League Baseball (MLB) is the most historic professional sports league in the United States and consists of 30 member clubs in the U.S. and Canada, representing the highest level of professional baseball. Led by Commissioner Robert D. Manfred, Jr., MLB has achieved back-to-back attendance gains for the first time in 12 years with an overall increase of +11% and 80% of Clubs welcoming more fans over the last two seasons following extensive rule changes that have improved the quality of play on the field. With the 2024 season featuring the best time of game in 40 years and the most stolen bases in 109 years, MLB viewership increased across all its national media partners, grew international viewership by +18%, set another record for MLB.TV streaming with more than 14 billion minutes watched and earned League of the Year honors from Sports Business Journal and the CLIOS. As the league increased its marketing efforts and promotion of star players like 2024 NL MVP Shohei Ohtani and 2024 AL MVP Aaron Judge, MLB has significantly increased its younger fan base as evidenced through viewership, social media, ticket purchasing, and participation metrics. Through its MLB Together social responsibility efforts, MLB remains committed to making a positive impact in the communities of the U.S., Canada and throughout the world. With the continued success of MLB Network, MLB digital platforms and local media production and distribution, MLB continues to find innovative ways for its fans to enjoy America’s National Pastime and a truly global game. To learn more about MLB, please visit www.mlb.com.

ABOUT FANATICS

Fanatics is building a leading global digital sports platform. We ignite the passions of global sports fans and maximize the presence and reach for our hundreds of sports partners globally by offering products and services across Fanatics Commerce, Fanatics Collectibles, and Fanatics Betting & Gaming, allowing sports fans to Buy, Collect, and Bet.

Through the Fanatics platform, sports fans can buy licensed fan gear, jerseys, lifestyle and streetwear products, headwear, and hardgoods; collect physical and digital trading cards, sports memorabilia, and other digital assets; and bet as the company builds its Sportsbook and iGaming platform.

Fanatics has an established database of over 100 million global sports fans; a global partner network with approximately 900 sports properties, including major national and international professional sports leagues, players associations, teams, colleges, college conferences and retail partners, 2,500 athletes and celebrities, and 200 exclusive athletes; and over 2,000 retail locations, including its Lids retail stores.

Our more than 22,000 employees are committed to relentlessly enhancing the fan experience and delighting sports fans globally.

For additional information please visit www.fanaticsinc.com.

COMPLEX PRESENTS TAKASHI MURAKAMI x MLB LIMITED EDITION COLLECTION FOR 2025 MLB TOKYO SERIES
COMPLEX PRESENTS TAKASHI MURAKAMI x MLB LIMITED EDITION COLLECTION FOR 2025 MLB TOKYO SERIES

COMPLEX PRESENTS TAKASHI MURAKAMI x MLB LIMITED EDITION COLLECTION FOR 2025 MLB TOKYO SERIES
COMPLEX PRESENTS TAKASHI MURAKAMI x MLB LIMITED EDITION COLLECTION FOR 2025 MLB TOKYO SERIES

 

Photo – https://laotiantimes.com/wp-content/uploads/2025/02/mkk_mlb.jpg

Photo – https://laotiantimes.com/wp-content/uploads/2025/02/mlb_x_tmkk_lookbook19763.jpg

Photo – https://laotiantimes.com/wp-content/uploads/2025/02/press_2025_0213_mlb_x_tmkk_lookbook16103_4x5_final.jpg 

Logo – https://laotiantimes.com/wp-content/uploads/2025/02/complex_logo.jpg

Metabolon Unveils New Multiomics Biomarker Discovery Functionality via its Industry-leading Integrated Bioinformatics Platform

Metabolon’s expertise extends beyond metabolomics to include data insights and software solutions for multiomics research

MORRISVILLE, N.C., Feb. 27, 2025 /PRNewswire/ — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces new multiomics biomarker discovery capabilities within Metabolon’s recently launched Integrated Bioinformatics Platform. This new functionality includes multiomics predictive modeling, latent factor analysis, multiomics pathway analysis using public tools like Reactome, and sophisticated multiomic data visualization resources.

The global multiomics market was valued at $2.4 billion in 2023 and is projected to reach $6.4 billion by 2030.  Since 2012, scientific publications featuring multiomic data have increased 63% annually.  Despite the growing importance of multiomics research, successfully combining genomic, transcriptomic, proteomic, and metabolomic data can be time-consuming and expensive.  Metabolon’s new multiomics biomarker discovery functionality provides powerful and easily accessible online bioinformatics tools that enable multiomics research and provide the most complete out-of-the-box representation of the phenotype available.

“Metabolon’s new multiomic biomarker discovery capabilities make integrating disparate omics data sets easier and help our customers build powerful studies that incorporate metabolite and lipid data seamlessly with other omics information,” said Dr. Karl Bradshaw, Chief Business Officer at Metabolon.

“Reactome’s comprehensive and expertly curated pathway data provides a critical foundation for multiomic analysis,” said Dr. Lincoln Stein, Lead Principal Investigator at Reactome.  “We’re thrilled to see Metabolon harnessing our resource to enable researchers to unravel the complexities of biological systems.”

Metabolon’s new bioinformatics functionality is available via a comprehensive suite of web-based tools:

Multiomics Predictive Modeling

  • Upload and integrate diverse omics data using algorithms like logistic regression and random forest to build multiomics models.
  • Explore model performance and evaluate multiomic feature contributions to identify potential biomarkers for further analysis.

Latent Factor Analysis of Multiomics Data

  • Identify latent factors representing underlying biological variation.
  • Explore relationships that span multiomic layers to uncover biologically relevant biomarkers and guide further research.

Multiomics Pathway Enrichment Analysis Using Reactome (https://reactome.org/)

  • Map metabolites to other omics entities (e.g., genes and proteins) using the most comprehensive and curated reference of biological pathways.
  • Statistically rank pathways from the Reactome database that are driving variation/signal found in your specific dataset.

Leverage Metabolon’s integrated bioinformatics platform to gain improved insights into your most critical research questions – explore the interplay of your biomarkers and their effects on wider-reaching biological mechanisms.  To learn more, please visit:

About Metabolon 
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies.  With more than 20 years, 10,000+ projects, 3,400+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques.  Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library.  Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success.  The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management.  For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

About Reactome
Reactome is an open-source, open-access, manually curated, and peer-reviewed pathway database.  Our goal is to provide intuitive bioinformatics tools for the visualization, interpretation, and analysis of pathway knowledge to support basic and clinical research, genome analysis, modeling, systems biology, and education.  Founded in 2003, the Reactome project is led by Lincoln Stein of OICR, Peter D’Eustachio of NYU Langone Health, Henning Hermjakob of EMBL-EBI, and Guanming Wu of OHSU.  The Reactome database and website enable scientists, researchers, students, and educators to find, organize, and utilize biological information to support data visualization, integration, and analysis.

About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system.  Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.